Use Of Oral Janus Kinase Inhibitors For The Treatment Of Severe Alopecia Areata: Narrative Review And Real-World Experience
March 2026
in “
Immunological Medicine
”
Research cited in this study
31 / 31 resultsresearch Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
research Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata
research Safety of Oral JAK Inhibitors in Treating Alopecia Areata: A Systematic Review and Network Meta-Analysis
Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.
research Long-Term Real-World Outcomes of Baricitinib in Severe Alopecia Areata: A 104-Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
Baricitinib is generally safe for long-term use in treating severe alopecia areata.
research Understanding Eyebrow and Eyelash Involvement in Patients with Alopecia Areata and Responsiveness to Treatment with Baricitinib
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Predictive Factors for Treatment Responses to Baricitinib in Severe Alopecia Areata: A Retrospective, Multivariate Analysis of 70 Cases from a Single Center
Certain patient traits can predict better hair regrowth with baricitinib in severe alopecia areata.
research Long-Term Safety and Efficacy of Ritlecitinib in Adults and Adolescents with Alopecia Areata and at Least 25% Scalp Hair Loss: Results from the ALLEGRO-LT Phase 3, Open-Label Study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Real-Life Effectiveness and Safety of Baricitinib in 17 Japanese Patients With Alopecia Areata: A 60-Week Single Center Study
Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.
research Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year
Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
research Systematic Review and Indirect Treatment Comparisons of Ritlecitinib Against Baricitinib in Alopecia Areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.
research Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Baricitinib Therapy for Moderate to Severe Alopecia Areata: A Retrospective Review of 95 Japanese Patients
research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata
Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Economic Burden of Alopecia Areata: A Study of Direct and Indirect Cost in Japan Using Real-World Data
Alopecia areata causes a significant economic burden in Japan, mainly due to productivity loss.
research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research Prevalence of Alopecia Areata in Japan: Estimates from a Nationally Representative Sample
Alopecia areata affects 1.45% of people in Japan, impacting mood and self-esteem, with many not seeking treatment.
research Maintenance, Withdrawal, and Re-Treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-Blind Extension of a Phase 2a Randomized Clinical Trial
Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.
research Two Cases in Which Tofacitinib Effectively Treated Both Ulcerative Colitis and Alopecia Areata
Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.
research What Is Behind the 'Swarm of Bees' in Alopecia Areata
Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.
research Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis
People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.
research Alopecia Areata: A Review of Disease Pathogenesis
Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012
Guidelines suggest various treatments for alopecia areata, but leaving it untreated is also an option as 80% cases may recover on their own.
research Alopecia Areata: An Autoimmune Disease Causing Hair Loss
Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.
research Prevalence of Dermatological Disorders in Japan: A Nationwide, Cross-Sectional, Seasonal, Multicenter, Hospital-Based Study
Eczema and fungal infections are the most common skin problems in Japan, with different age groups and genders affected by various conditions.
research Maintenance of Hair Follicle Immune Privilege Is Linked to Prevention of NK Cell Attack
Hair follicles prevent NK cell attacks to avoid hair loss.
research Androgen-Inducible TGF-β1 from Balding Dermal Papilla Cells Inhibits Epithelial Cell Growth: A Clue to Understanding Paradoxical Effects of Androgen on Human Hair Growth
Androgens may cause hair loss by increasing TGF-beta1 from scalp cells, which inhibits hair cell growth.
Similar Research
5 / 1000+ results
research Effectiveness and safety of oral Janus kinase inhibitors in patients aged ≤12 with alopecia areata: a systematic review and meta-analysis
Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
research Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
research Delivery Strategies of siRNA Therapeutics for Hair Loss Therapy
Effective delivery systems are crucial for siRNA hair loss treatments to work better.
research Safety of Alopecia Treatments in Patients with Breast Cancer and High-Risk Women: A Review
Alopecia treatments like 5α-reductase inhibitors and spironolactone are safe for breast cancer patients and high-risk women.
research Alemtuzumab-Induced Secondary Autoimmune Skin Disorders as Side Effects of Multiple Sclerosis Therapy: Problem That Can Be Influenced or Fate? A Narrative Overview of The Literature A Neuroprotective Role of Vitamin D?
Taking vitamin D might improve life for MS patients and reduce skin side effects from alemtuzumab treatment.